Research progress on long non-coding RNA in renal cell carcinoma

doi:10.19401/j.cnki.1007-3639.2016.08.011

China Oncology ›› 2016, Vol. 26 ›› Issue (8): 704-711.doi: 10.19401/j.cnki.1007-3639.2016.08.011

Previous Articles Next Articles

Research progress on long non-coding RNA in renal cell carcinoma

HE Anbang, CHEN Haodong, LÜ Zhaojie, YANG Jiangeng, MEI Hongbing

Department of Urology, Shenzhen Second People’s Hospital, Clinical Medicine College of Anhui Medical University, Shenzhen 518035, Guangzhou Province, China

Online:2016-08-30 Published:2016-10-19
Contact: MEI Hongbing E-mail: hbmei68@163.com

Abstract

Abstract: Long non-coding RNA (lncRNA) is a class of RNA molecules, transcripted by RNA polymerase Ⅱ, which consists of more than 200 nucleotides and protein-coding function. Many studies have indicated that lncRNA plays an important role in epigenetics, transcription and post-translational processing. The abnormal expression of lncRNA significantly correlates with occurence, development, and metastasis of renal cell carcinoma (RCC) and prognosis of the patients with RCC. This paper summarizes the advances in the research on lncRNA in RCC to reveal the mechanisms of the disease at the molecular level, in order to provide new methods of prevention, diagnosis, treatment and prognostic assessment of RCC.

Key words: Long non-coding RNA, Renal cell carcinoma, Targeted therapy

HE Anbang, CHEN Haodong, Lü Zhaojie, et al. Research progress on long non-coding RNA in renal cell carcinoma[J]. China Oncology, 2016, 26(8): 704-711.

[1]	LEI Kunyang, XIE Wenjie, SUN Ting, LIU Yifu, WANG Xu. Expression and effect of long non-coding RNA ARAP1-AS1 in clear cell renal cell carcinoma [J]. China Oncology, 2022, 32(1): 34-40.
[2]	JIN Youping, LI Luying, ZHOU Ping. A study on the role of long non-coding RNA STMN1P2 in breast cancer and its mechanism [J]. China Oncology, 2021, 31(7): 596-604.
[3]	ZHU Jun, WU Xiaohua. Leading research progress and prospect of gynecological oncology in 2020 [J]. China Oncology, 2021, 31(4): 250-256.
[4]	GUO Ye , ZHANG Chenping . Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2021 edition) [J]. China Oncology, 2021, 31(12): 1220-1232.
[5]	ZHANG Xin , ZHOU Cheng , ZHOU Kaiqian , BAI Qianming , JIANG Dongxian , SUJIE Akesu , HOU Yingyong , WANG Zheng , JI Yuan . MET gene amplification and its prognostic role in sarcomatoid hepatocellular carcinoma [J]. China Oncology, 2020, 30(9): 641-649.
[6]	TONG Ying, YU Yiwen, XIE Suhong, WANG Yanchun, LU Renquan, GUO Lin. Effects of silent information regulator 4 overexpression or glutamine deprivation on apoptosis and proliferation of clear cell renal cell carcinoma [J]. China Oncology, 2020, 30(6): 435-440.
[7]	ZHANG Lianglong , AN Hongwei , ZHAO Lizhi , DONG Qian , GAO Guiyan . Mechanism of overexpression of lncRNA LINC00152 in temozolomide-induced stem cell cycle arrest in glioma [J]. China Oncology, 2020, 30(5): 328-334.
[8]	HONG Shaodong, ZHANG Li. Recent advances and prospect in targeted therapy for lung cancer [J]. China Oncology, 2020, 30(10): 733-743.
[9]	ZHOU Hongyu, CHEN Lihua, LI Haoran, CHENG Xi. The role of c-kit in the treatment and prognosis of primary female genital malignant melanoma: current status and prospects [J]. China Oncology, 2020, 30(10): 834-840.
[10]	YANG Lingge, WANG Chunmeng. Drug therapy for alveolar soft part sarcoma: current status and progress [J]. China Oncology, 2019, 29(9): 746-752.
[11]	TIAN Xi, XU Wenhao, QU Yuanyuan, WANG Jun, WANG Hongkai, CAO Dalong, SHI Guohai, ZHANG Hailiang, YE Dingwei. Clinical features of renal cell carcinoma carrying second primary estrogen-related tumors: propensity score matching analysis [J]. China Oncology, 2019, 29(12): 941-947.
[12]	CAO Xiaoshan, CONG Binbin. The progress of treatment for triple-negative breast cancer in the era of precision medicine [J]. China Oncology, 2019, 29(12): 971-976.
[13]	XU Mingbin, ZHAO Yutong, LI Chengyang, ZHAO Jiawen, MA Chenjun, LIAO Naikai, YANG Zhanbin, CHENG Jiwen. Predictive value of lymphocyte-to-monocyte ratio and serum albumin in patients with clear cell renal cell carcinoma [J]. China Oncology, 2019, 29(11): 887-898.
[14]	LIANG Xiaohua, HUANG Ruofan, ZHAN Qiong. Shanghai expert consensus on the management of brain metastasis of non-small cell lung cancer with driver gene mutations [J]. China Oncology, 2019, 29(1): 71-80.
[15]	LI Linhai, XIAO Bin, GUO Zixuan, et al. GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis [J]. China Oncology, 2018, 28(8): 561-566.

Research progress on long non-coding RNA in renal cell carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments